Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $823,478 | $6,175,000 | $6,465,000 | $7,436,000 |
| % Growth | -86.7% | -4.5% | -13.1% | – |
| Cost of Goods Sold | $957,336 | $1,426,000 | $1,589,000 | $1,600,000 |
| Gross Profit | -$133,858 | $4,749,000 | $4,876,000 | $5,836,000 |
| % Margin | -16.3% | 76.9% | 75.4% | 78.5% |
| R&D Expenses | $79,849 | $851,000 | $834,000 | $981,000 |
| G&A Expenses | $0 | $2,019,000 | $1,776,000 | $3,190,000 |
| SG&A Expenses | -$513,615 | $2,019,000 | $1,776,000 | $3,190,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $869,000 | $908,000 | $3,000 |
| Operating Expenses | -$433,766 | $3,739,000 | $3,518,000 | $4,174,000 |
| Operating Income | $299,909 | $1,010,000 | $1,358,000 | $1,662,000 |
| % Margin | 36.4% | 16.4% | 21% | 22.4% |
| Other Income/Exp. Net | -$726,368 | -$216,000 | -$262,000 | -$225,000 |
| Pre-Tax Income | -$426,459 | $794,000 | $1,096,000 | $1,437,000 |
| Tax Expense | -$119,879 | $160,000 | $221,000 | $47,000 |
| Net Income | -$306,581 | $636,000 | $875,000 | $1,397,000 |
| % Margin | -37.2% | 10.3% | 13.5% | 18.8% |
| EPS | -0.89 | 1.85 | 2.55 | 4.07 |
| % Growth | -148.1% | -27.5% | -37.3% | – |
| EPS Diluted | -0.89 | 1.83 | 2.52 | 4.03 |
| Weighted Avg Shares Out | 344,649 | 343,727 | 343,453 | 343,227 |
| Weighted Avg Shares Out Dil | 344,649 | 347,170 | 346,973 | 347,062 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $17,791 | $216,000 | $262,000 | $225,000 |
| Depreciation & Amortization | $795,839 | $889,000 | $938,000 | $932,000 |
| EBITDA | $387,276 | $1,899,000 | $2,296,000 | $2,593,000 |
| % Margin | 47% | 30.8% | 35.5% | 34.9% |